



www.epa.gov

Development of Thyroid Deiodinase Knockout *Xenopus tropicalis* Using CRISPR/Cas12a

Gene Editing Towards Establishment of an Amphibian Adverse Outcome Pathway

Sally Mayasich^{1,2}, Philip DeGoey², Jonathan Haselman², Sigmund Degitz²

¹ORISE/ORAU Research Participation Program, ²U.S. EPA, ORD, CTE, Great Lakes Toxicology & Ecology Division (GLTED), Duluth, MN



Sally Mayasich | mayasich.sally@epa.gov | 218-529-5122

Introduction and Objectives

Three iodothyronine deiodinase enzymes, identified in both mammals and amphibians, are selenoproteins anchored in the cell membranes. DIO1 and DIO2 catalyze the removal of an iodine from thyroid hormones to activate the hormone in specific tissues at appropriate times, and the DIO3 inactivates the hormone when it is no longer needed. We used the clustered regularly interspaced short palindromic repeat (CRISPR) /Cas12a (Cpf1) system to disrupt type 2 and type 3 iodothyronine deiodinase enzyme genes (*Xtdio2* and *Xtdio3*) in *Xenopus tropicalis* zygotes. The objectives of gene disruption are to:


- Significantly decrease or knock out the expression of a specific protein target in the thyroid system to
- Identify molecular initiating events, key events and adverse outcomes for Adverse Outcome Pathway (AOP) development to
- Predict the effects in amphibians of chemicals that inhibit deiodinases. For example, our ToxCast chemical screening identified several strong inhibitors of *Xenopus* dio3 activity.*

CRISPR/Cas12a (LbCpf1) crRNA design and microinjection methods

- Guide RNA design was aided using [CRISPRscan](#) and [CRISPR RGEN tools Cas-designer](#). The CRISPR guide RNA oligos (crRNA) were synthesized by Integrated DNA Technologies. Effective crRNAs were selected through *in vitro* digestion of a PCR-generated genomic DNA segment containing the target site, incubated with a ribonucleoprotein (RNP) complex formed between *X. tropicalis* dio2 or dio3 crRNA and LbCpf1 enzyme (New England Biolabs; NEB). The [NEB protocol](#) was used, with modifications.
- X. tropicalis* adults were induced to spawn by hCG injection; eggs were collected and treated with L-cysteine rinse; single-cell zygotes were sorted into 1/9x Modified Ringers with 3% Ficoll.
- Preparation of the microinjection cocktail followed [Moreno-Mateos et al. \(2017\)](#), with modifications. Single-cell-stage fertilized embryos (zygotes) were injected with ~2 nl (20 fmol) of either the *dio2* or *dio3* RNP complex in Cpf1 working buffer (20mM Hepes pH 7.5, +KCl+MgCl2+TCEP+glycerol) with 0.01% phenol red.
- Following 24-30 hours of incubation at 25°C in 1/9x MR, embryos were transferred to 4.5 L flow-through tanks delivering Lake Superior Water @ ~25 mL/min.

U.S. Environmental Protection Agency
Office of Research and Development


Microinjection of RNP complexes into *X. tropicalis* zygotes



Rapid, non-invasive swab DNA extraction and polymerase chain reaction (PCR) genotype screening




Results and Adverse Outcome Pathway (AOP) Development




Chemicals that could alter amphibian metamorphosis through inhibition of type 3 deiodinase enzyme.*	Xenopus dio3 IC50 (μM)
Chlorothalonil	0.67
Fipronil	0.88
Fluazinam	2.27
Triflumizole	2.77
Pentachloropyridine	6.17
SSR69071	7.83
Quinoxifen	7.88
Bisphenol A diglycidyl ether	8.91
Pirimicarb	11.53
Oclothionone	13.05
Dichloro	13.8


*Results of *in vitro* screening assays performed at U.S. EPA-GLTED on recombinant *X. laevis* dio3 enzyme (Mayasich et al. to be submitted to *Toxicological Sciences*.)



Accelerated metamorphosis in *dio2* crispants




Precocious metamorphosis leads to high mortality in *dio3* crispants



Future Directions

- Surviving crispants will be cross-bred to attempt complete knockout of the *dio2* and *dio3* genes in *X. tropicalis* F2 generation.
- Sequencing;
- serum analyses for T3 and T4; and
- TH-dependent gene expression analyses will be conducted.



Acknowledgements

We thank Jessica Christensen for aid in development of the microinjection protocol and Jeff Denny, Thomas Lerdall, Joe O'Flanagan and Jennifer Olker (USEPA/GLTED) for assistance with microinjections.